FROM THE ORGANIZERS OF DRUG DELIVERY PARTNERSHIPST

CINE BUSIN**ESS** CONGRESS WHERE DEVELOPMENT DEALS GET DONE

THE HILTON BALTIMORE

The only place to meet the innovators behind the top 10 vaccines partnerships, sharing their secrets to success and providing particpants with the tools for partnering and funding.

Home

Agenda

Who Should Attend

Advisory Board

Speaking Faculty

Venue & Pricina

Contact Us

Partners

Send to a friend

Home

DOWNLOAD BROCHURE













Email: Password: GO

Sign Up Remember me

10 VACCINE PARTNERSHIPS



Intercell & GSK Surviving and thriving in an acquisition-oriented economy

Katherine Cohen, PhD INTERCELL Michel Baijot. GSK



Nabi Biopharmaceuticals & GSK

Maintaining strong brand identities while in strategic partnerships with big Pharma

Raafat Fahim, PhD NABI BIOPHARMA-CEUTICALS



BioSante Pharmaceuticals & Cell

Genesys Ensuring small Biotech survival when big Pharma deals aren't forthcoming

Stephen M. Simes BIOSANTE PHARMACEUTICALS



Globelmmune & Celgene

Making your vaccine commercially attractive in a crowded marketplace

GLOBEIMMUNE



Novavax & Cadila **Pharmaceuticals**

Securing the right emerging market partnership for your platform

Rahul Singhvi, ScD, MBA NOVAVAX



Sanofi Pasteur & Syntiron Attracting big Pharma to your vaccine platform

Gavin Zealey SANOFI-Joseph Shaw SYNTIRON



National Cancer Institute & Bavarian

Nordic Tackling challenges to deliver a therapeutic platform

James Gullev, MD NIH/NATIONAL CANCER INSTITUTE Jurgen Langharig, PhD BAVARIAN NORDIC



Medicago & DARPA Navigating the comple world of government

Frederic Ors MEDICAGO



Merck & The Wellcome Trust Benefits of Public/Private partnerships

Mark Feinberg, MD MERCK & CO. INC



Vaxinnate & Venture Is the pulse of venture capita still beating?

Alan Shaw, PhD VAXINNATE Seth Rudnick, MD CANAAN PARTNERS



VACCINES are the continuing success story, earning

By 2012, vaccines are expected to bring in more than \$35 billion in revenue.

Business development heads must take a long hard look at their company's pipelines and pursue stronger vaccine portfolios. As the global demand for vaccines and their profitability continue to soar, pharmaceutical and biotech companies are increasingly looking for ways to secure the most lucrative partnerships possible to advance their vaccine platform development.

The Vaccine Business Congress is the only conference solely dedicated to fostering partnering opportunities in the vaccine space. Here, we bring together all of the major players in vaccine development, including big Pharma, small biotech, government, philanthropic organizations, and private investment companies. Participants obtain with the tools to secure funding for their vaccine platforms, so they can stay competitive in a booming market in both developed and emerging markets.

The Vaccine Business Congress features 10 case studies from the top vaccine partnerships since 2008. These decision-makers share their secrets to success to help you get the funding you need for vaccine development.

In three days:

rs of behind successful vaccine partnerships Hear from t

Identify the most accessible emerging market opportunities for your company

Hear from the key innovators of behind successful vaccine partnerships identify what big Pharma Icoks for when deciding on partnering in vaccine development Make your biotech more attractive to big Pharma and venture capitalists. See the most exciting new vaccine products and technologies biotechs have to offer Experience hours of face to face networking time with leaders in vaccine business development.

Partnering Activities

The Vaccine Business Congress facilitates face-to-face meetings with the people you want to talk to through these tools:

Pipeline Previews: 5 minute rapid fire presentations in front of the entire audience to reveal new products and innovations in vaccine

development.

Solution Showcases: 15 minute sessions presented by leading solution providers to introduce you to the services available to minimize the cost of development, research and commercialization.

The Vaccine Business Congress Solutions Center: The exhibition hall featuring leading innovators in vaccine partnering and

Quick Connection Sessions: Speed Networking sessions during designated networking time in the Vaccine Business Congress

Match Making Meetings: Attendees schedule on their own during designated networking times.

One on One Speaker/Sponsor Meetings: May be scheduled during certain sessions or during networking breaks (TBD).

Register | Contact | Home | Updates © 2008-2009 IIR HOLDINGS, LTD. All Rights Reserved.



Home

Agenda

Who Should Attend

Advisory Board

Speaking Faculty

Venue & Pricing

Contact Us

Partners

Send to a friend









Workshop Day | Wednesday, March 2, 2011

- Registration and Morning Coffee
- Understand the Changes in the National Vaccine Plan to Maximize Government Sponsored Funding and <mark>Avoid FDA Scrutiny</mark> 9:00

Part I National Vaccine Plan

- 10:30 30 Minute Morning Networking Break
- 11:00 Part II Public Health Emergency Medical Countermeasure Enterprise
- 12:30 Lunch for Workshop Participants
- Explore Emerging Markets to Successfully Implement Your Vaccine Platform and Expand Your 1:30 **Global Footprint**

Part I The View from Inside — Emerging Market Perspective Subhash Kapre, Executive Director, SERUM INSTITUTE OF INDIA

- 30 Minute Networking and Refreshment Break 3:00
- Part II The View from Outside Developed Market Perspective
 Regina Rabinovich, MD, Director, Infectious Diseases, Global Health Program, THE BILL AND MELINDA GATES FOUNDATION

End of Workshop Day

Key Legend Look for these icons to identify the sessions



Solution Showcase



Keynote





Vaccine Partnership Spotlight











Email Password: GO

Sign Up Remember me

Main Conference, Day One | Thursday, March 3, 2011

- 7:30 Registration and morning coffee
- 8:00 **Chairperson's Welcome and Opening Remarks**
- Navigating the Vaccine Development Deal Landscape How the Loss of the "Middle Class" will Shape the Future of Vaccine Partnering

Thomas P. Monath, MD, Partner, Pandemic and Biodefense Fund, KLEINER PERKINS CAUFIELD & BYERS, Adjunct Professor, HARVARD SCHOOL OF PUBLIC HEALTH, Formerly Chief Scientific Officer and Executive Director, ACAMBIS



GlaxoSmithKline and Intercell

Michel Baijot, Vice President, Development and Strategic Alliances, **GSK** Katherine Cohen, PhD, Senior Vice President, Global Head Corporate and Business Development, **INTERCELL**



Nabi Biopharmaceuticals and GSK

Raafat Fahim, PhD, President and CEO, NABI BIOPHARMACEUTICALS



Create a Profitable Partnership to Achieve a Win-Win for Both Parties

Katherine Cohen, PhD, Senior Vice President, Global Head Corporate and Business Development, INTERCELL Raafat Fahim, PhD, President and CEO, NABI BIOPHARMACEUTICALS

10:20



Special Presentation The Lone Ranger - Right on Target in Cancer Vaccine Development - The Story of Dendreon

Greg Schiffman, Senior Vice President and CFO, DENDREON



Hot Topic Debate Can Biotechs still Secure Private and Public Investment to Take One or More **Products All the Way Through Clinical Development to Commercialization?**

Lance Gordon, PhD, CEO, IMMUNOBIOLOGICS, former CEO, VAXGEN, ORAVAX AND NORTH AMERICAN VACCINES, Board of Trustees, SABIN VACCINE INSTITUTE

Jeffrey Hackman, SVP, Commercial Operations, INTERCELL Mark Monane, MD, Senior Analyst, Biotechnology & Life

Sciences, NEEDHAM & COMPAN
Greg Schiffman, Senior Vice President and CFO, DENDREON>

11:50 **Pipeline Previews**



12:10 Luncheon for Faculty and Participants

BioSante Pharmaceuticals and Cell Genesys

Stephen M. Simes, President and CEO, BIOSANTE PHARMACEUTICALS



Determine How Biotechs Strategically Shift Their Business Models to Meet Pipeline Development

Jürgen Langhärig, PhD, MBA, VP Business Development, BAVARIAN NORDIC
Janice Kimpel, VP, Business Development, ALPHAVAX Stephen M. Simes, President & CEO, BIOSANTE PHARMACEUTICALS

Solution Showcase



2:45

Networking Break



Globelmmune and Celgene

Timothy Rodell, MD, President and CEO, GLOBEIMMUNE

Gad Soffer, VP, Business Development, CELGENE



Navigate a Crowded Marketplace to Make Your Vaccine Commercially Attractive

David Kirke, Associate Director, **ERA CONSULTING**Jennifer R. Hannesschlager, PhD, Principal, **TIBER CREEK PARTNERS, LLC**Timothy Rodell, MD, President and CEO, **GLOBEIMMUNE**

Gad Soffer, VP. Business Development, CELGENE



Pipeline Previews



Novavax and Cadila Pharmaceuticals



Rahul Singhvi, ScD, MBA, CEO, NOVAVAX



Secure the Right Emerging Market Partnership for Your Platform to Maximize Your Market Share in a **Vast Global Economy**

Anthony Ford-Hutchinson, PhD, Senior Vice President, Vaccines Research and Development, MERCK RESEARCH LABORATORIES

Subhash Kapre – Executive Director, SERUM INSTITUTE OF INDIA
Regina Rabinovich, MD, Director, Infectious Diseases, Global Health Program, THE BILL AND MELINDA GATES FOUNDATION

Rahul Singhvi, ScD, MBA, CEO, NOVAVAX

Close of Day One

Main Conference, Day Two | Friday, March 4, 2011

7:30

8:30 **Chairperson's Opening Remarks**



Sanofi-pasteur and Syntiron

Gavin Zealey, Sr. Director, Corporate Development, SANOFI-PASTEUR Joseph Shaw, CEO, SYNTIRON



What are Big Pharma BD Chiefs Looking For?

Michel Baijot, VP, Development and Strategic Alliances, **GSK**Riccardo Manetti, Global Head, Global Head of Search and Evaluation, Business Development and Licensing, **NOVARTIS** VACCINES & DIAGNOSTICS AG
Michael N. Robertson, MD, Senior Director, External Scientific Affairs, MERCK & CO., INC

Gavin Zealey, Senior Director, Corporate Development, SANOFI-PASTEUR



Pipeline Previews

10:00 Networking Break





Frederic Ors, VP, Business Development, MEDICAGO



National Cancer Institute and Bavarian Nordic

James Gulley, MD, PhD, Director Clinical Trials Group, NATIONAL CANCER INSTITUTE / NATIONAL INSTITUTES OF

Jürgen Langhärig, PhD, VP Business Development, BAVARIAN NORDIC

11:00 Tackle Challenges to Deliver a Therapeutic Vaccine Platform in a High Risk Environment

Joyce Pei, Director, Global Strategy, ROCHE PHARMA PARTNERING

11:40

Navigate the Complex World of Government Partnerships to Secure Funding for Your Vaccine Platform

Gerald Kovacs, MD, Director, Division of CBRN Countermeasures, BARDA, Assistant Secretary for Preparedness and Response, US DEPARTMENT OF HEALTH AND HUMAN SERVICES
James Gulley, MD, PhD, Director Clinical Trials Group, NATIONAL CANCER INSTITUTE/ NATIONAL INSTITUTES OF HEALTH

12:10 Luncheon for Speakers and Attendees

1:10

Solution Showcase



Merck and the Wellcome Trust with Discussion on the Benefits of Public/Private Partnerships



Mark Feinberg, MD, PhD, Head of Medical Affairs, Vaccines, MERCK & CO. INC



VaxInnate Continues to Secure VC Funding Across its Pipeline

Alan Shaw, PhD, CSO, and Chairman of the Board, VAXINNATE Seth Rudnick, MD, Venture Partner, CANAA N PARTNERS



Determine What Attracts Investors in a Gun Shy Economy and Whether the Pulse of Vaccine Capital is Still Beating

Douglass Given, MD, President and CEO, VIVALDI BIOSCIENCES, Investment Partner, BAY CITY CAPITAL Stephen Knight, Managing Partner, FIDELITY VENTURE HEALTHCARE Eric Aguiar, Partner, THOMAS MCNERNEY

Fred Schwarzer, Managing Partner, CHARTER LIFE SCIENCES

2:50	2010 Vaccine Excellence in Partnering Awards Presentation
3:10	Closing Remarks from Conference Chair

3:30 Close of The Vaccine Business Congress – See you next year!

Register | Contact | Home | Updates © 2008-2009 IIR HOLDINGS, LTD. All Rights Reserved



Home

Agenda

Who Should Attend

Advisory Board

Speaking Faculty

Venue & Pricing

Contact Us

Partners

Send to a friend

Home

DOWNLOAD BROCHURE VACCINE BUSINESS Q 2 2 9












Sign Up Remember me

WHO WILL YOU MEET?



This event is designed for CEOs, COOs, CMOs, CFOs, SVPs, EVPs, VPs, Global Directors, Global Heads, Heads, Executive Directors, Senior Directors, Directors, Managing Partners, Partners, Principals, and Associates with titles in the following areas:

Business Development - 30%

Vaccines R&D - 20%

C-Level Executives - 17%

W Licensing - 15%

W Venture Capitalist - 8% W Financial Analyst - 5%

Strategic Alliances - 5%

Companies Attending Past Partnering & Vaccine Events:

W

W

3M Company

Acambis Inc AktivDry

AlphaVax Inc

Aridis

BALM Inc

Big DNA

Bill and Melinda Gates Foundation

BN ImmunoTherapeutics Incorporated

Cangene Corporation

Cellular Technology Limited

Datamonitor Inc

Dicerna Pharmaceuticals

Dow Chemical

Eisai Research Institute

Emory University

Eurocine Vaccines AB

Genetix Limited

Genzyme Corporation

Georgia Tech

GlaxoSmithKline Biologicals SA

ImmunoBiology Ltd

Immunovaccine Technologies

Integrity Biosolution

Inter Cell USA

Intervet Inc Keynote

Kinesis Pharma

Liquidia Technologies Inc

Lyophilization Technology

MedImmune Inc

Memorial Sloan Kettering Cancer Ctr

Merck & Company Inc

Merial

National Institute of Health

NIH/NCI National Institutes of Health

Novartis Vaccines & Diagnostics

Novavax Inc

ODC Therapy PATH

Pfizer Inc

PPD

Protein Therapeutics Purdue University

Sanofi Pasteur Inc

SBL Vaccines

Schering Plough

Schott North America Inc

Stabilitech Ltd

Stryker Biotech

SUNY Downstate University

Takeda Pharmaceutical Products Inc Tulane University School of Medicine

University of Colorado at Boulder

University of London

Vaxine

Vaxinnate Corporation

VaxOnco

Vical Inc

VIRxSYS Corporation

Wyeth Research & Development

Register | Contact | Home | Updates © 2008-2009 IIR HOLDINGS, LTD. All Rights Reserved.

FROM THE ORGANIZERS OF DRUG DELIVERY PARTNERSHIPST

CCINE BUSIN**ESS** CONGRESS WHERE DEVELOPMENT DEALS GET DONE

THE HILTON BALTIMORE

Media Partners

Home

Agenda

Who Should Attend

Advisory Board

Speaking Faculty

Venue & Pricina

Contact Us

Partners

Become a Sponsor

Become a Media Partner

Become an Exhibitor

Send to a friend

Home

BioBusiness.TV

BioBusiness.TV is the first independent Internet TV Network for Life Sciences Investors and Executives. We create video-based industry focused business news and analysis programs. We produce and syndicate videos ranging from news and stock picks, to equity analyst insights, as well as C-level executive interviews on strategy, management, policy, marketing, science and more. http://www.biobusiness.tv




🎒 Adis

a Wolters Kluwer business BioDrugs

BioDrugs is an essential resource for R & D professionals and clinicians with an interest in biologic therapies, covering the development and use of biotechnology-based pharmaceuticals and innovative technologies for the treatment of human disease. Published by Adis, a Wolters Kluwer business. For this and other titles on personalised medicine and clinical pharmacology, please visit AdisOnline.com/BioDrugs

http://www.AdisOnline.com









DATAMONITOR

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Packaged Goods, Energy & Sustainability, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Sourcing, Technology and Telecoms industries. http://www.datamonitor.com

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and roduction of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today http://www.fiercevaccines.com











Email: Password:

Sign Up Remember me

www.mdbpartners.com

MDB Partners

MD Becker Partners is a boutique management and strategy consulting firm focusing on both public and private companies in the life sciences industry. The firm also works with venture capitalists, institutional investors, and others that provide capital to these companies. As a strategic supporter and partner, everything MD Becker Partners does is focused on helping its clients increase visibility, unlock stakeholder value and access resources to grow their business. To accomplish this, the firm integrates strategy, relations, and operational capabilities and applies them to carefully conceived and expertly enacted tactics. For more information, visit the company's website www.mdbpartners.com and Life Science Digest newsletter at www.mdbpartners.com and Life Sc http://www.mdbpartners.com



Pharmaphorum

www.pharmaphorum.com is the exciting new online discussion and networking site for the pharma, medical devices and diagnostics industry. The site features topical articles with user comments, a live forum and directories for upcoming conferences and relevant companies. With a growing audience of industry executives engaging in debate, www.pharmaphorum.com is the place for people in healthcare to share ideas, discuss leading issues and network. http://www.pharmaphorum.com/



Pharma Voice

PharmaVOICE magazine, reaching more than 17,500 U.S.-based life-sciences executives, is the forum that allows business leaders to engage in a candid dialogue on the challenges and trends impacting the industry. PharmaVOICE, and its supporting VIEW publications, provide readers with insightful and thought-provoking commentary in a multiple-perspective format through forums, topics, and articles covering a range of issues from molecule through market. PharmaVOICE subscribers are also kept abreast of the latest trends and information through additional media resources, including WebLinx Interactive WebSeminars, Podcasts, Videocasts, White Papers, E-Surveys and e-Alerts. Additionally, PharmaVOICEMarketplace.com provides a comprehensive directory of products, services, and solutions for the life-sciences industry. To Raise Your VOICE, contact feedback@pharmavoice.com. http://www.pharmavoice.com

http://www.pharmavoice.com



http://www.thebiotechpanel.com

Register | Contact | Home | Updates © 2008-2009 IIR HOLDINGS, LTD. All Rights Reserved.